

The Thalassemias in Clinical Practice

Ashutosh Lal, MD

Director

Comprehensive Thalassemia Program

UCSF Benioff Children's Hospital

Oakland

Outline

- Thalassemia: definitions and pathophysiology
- Epidemiology
- Classification of thalassemia syndromes
- Diagnosis of thalassemia
- Treatment of thalassemia

Hemoglobin

- Hemoglobin is a tetramer of 2 pairs of unlike globin chains


2 alpha chains	2 beta chains	$\alpha_2\beta_2$	Adult hemoglobin or HbA
2 alpha chains	2 gamma chains	$\alpha_2\gamma_2$	Fetal hemoglobin or HbF
2 alpha chains	2 delta chains	$\alpha_2\delta_2$	Minor adult hemoglobin or HbA2

Alpha genes are encoded on chromosome 16

There are 2 copies of alpha genes on each Ch.16


Gamma, delta and beta genes are encoded on chromosome 11

There is a single copy of each of these genes on each Ch.11



Adult

Hb A: $\alpha_2 \beta_2$



Fetal

Hb F: $\alpha_2 \gamma_2$

Thalassemias:

Quantitative defects of globin chain synthesis

Thalassemia

Inherited anemia

Inability to synthesize normal amounts of globin proteins

α thal: Decrease or absence of α -globin chains

β thal: Decrease or absence of β -globin chains

Thalassemia Trait

Heterozygote

Mild anemia that has insignificant effect on health

α thal trait

β thal trait

Thalassemia Disease


Heterozygote, Homozygote or Compound Heterozygote

Moderate or severe anemia

May not require transfusion:
Thalassemia intermedia

Requires regular transfusions:
Thalassemia major

Molecular Pathogenesis: beta thalassemia



Globin Genes

Globin Chains

Hemoglobin


Red Blood Cell


Normal

Beta-thalassemia Trait

Beta-thalassemia Major

Molecular Pathogenesis: alpha thalassemia






Normal

4 alpha genes


M: 14.5-16.5; F: 13-15



Silent Carrier

3 alpha genes, 1 del


M: 13-15.5; F: 11.5-13.5



Heterozygous α^0 Trait

2 alpha genes, 2 del


M: 12-14; F: 10.5-12.5



Homozygous α^+ Trait

2 alpha genes, 2 del


M: 12-14; F: 10.5-12.5



Hemoglobin H Disease

1 alpha gene, 3 del


M: 10-12; F: 8.5-10.5



Hemoglobin H Constant Spring

1 alpha gene, 1 mutation

M: 10-12; F: 8.5-10.5



Alpha Thal Major

0 alpha genes, 4 del

Severe Anemia in Fetus

Genetic basis of α thalassaemia

Two α genes (α_2 and α_1) are located on each Ch. 16

Common 1 gene deletions:

-3.7 Kb and -4.2 Kb

Common alpha mutation:

Constant Spring


Common 2 gene deletions:

SEA, MED, THAI, FIL

α^+ : 1 intact α gene

α^0 : 0 intact α genes

Transfusion Dependence in Thalassemia Syndromes




- Thal Trait
- Hb H Disease
- Heterozygous β thal intermedia

- E Beta Thal
- Hb H Constant Spring

- E Beta Thal
- Beta Thal Intermedia

- E Beta Thal
- Beta Thal Major
- Alpha Thal Major



Annual Births of Severe Thalassemia Syndromes

Modell 2008, Bull WHO


World

Distribution of Thalassemia in China




Adapted from Zeng & Huang. J Med Genet. 1987:578 and others

Distribution of Thalassemia in USA (estimated)



Distribution of Ethnicities at Oakland



Diagnosis of Thalassemia: Thalassemia Trait

- When to suspect thalassemia trait
 - Mild anemia Hemoglobin 10-12 g/dL
 - Microcytosis MCV <80
 - Hypochromia MCH <28
 - RBC count Normal or Increased
 - RDW Normal
- What is the best time to screen at risk population
 - Beta thal trait: at 1 year CBC
 - Alpha thal trait: At birth (currently not possible), otherwise at 1 year CBC
- Genetic counseling should follow screening
 - All activities should ideally take place in primary care practice
 - Prepare PCP's caring for at risk population to provide counseling for thalassemia trait
 - Different counseling for alpha and beta thalassemia

Diagnosis of Thalassemia Disease

- Prenatal diagnosis
 - When both parents are known carriers of thalassemia mutation
 - Test second parent if one parent is known thalassemia trait
 - Prenatal testing with CVS or amnio if both have beta trait or both have alpha trait
 - No consequence if one parent has alpha trait and one parent has beta trait
- Newborn screening for thalassemia syndromes
 - Possible to diagnose severe thalassemia syndromes
 - Alpha thalassemia: Hb Bart's
 - Beta Thalassemia: Hb F
 - E beta Thalassemia: Hb E
- Diagnosis of moderate or severe thal syndromes
 - CBC with hemoglobin <10 g/dL, microcytosis (sometimes mild), hypochromia, nucleated RBC
 - Splenomegaly, elevated bilirubin, growth impairment
 - Hemoglobin electrophoresis, DNA testing

Common Thalassemia Syndromes

- Beta thalassemias:

Condition	Genotype	Hemoglobin
Beta thal major	2 beta mutations	Hb <7 g/dL
Beta thal intermedia	2 beta mutations	Hb >7 g/dL
E beta thal	1 beta mutation with E mutation	Hb 4-9 g/dL



- Alpha thalassemias:

Condition	Genotype	Hemoglobin
HbH disease	3 alpha gene deletion	Hb 8-12 g/dL
HbH Constant Spring	2 alpha gene deletion + Constant Spring mutation	Hb 7-10 g/dL
Alpha thal major	4 alpha gene deletion	Fetal hydrops

Treatment of Thalassemia

- Deciding between regular transfusions and conservative management
- Pros and cons of transfusions
- Alternatives to transfusions
- Curative therapies

Transfusion Dependence in Thalassemia Syndromes



Comparison of Average Hemoglobin Levels

Individuals without
thalassemia

- 13-16 g/dL

Thalassemia intermedia not
receiving transfusions

- 6-9 g/dL

Thalassemia major receiving
regular transfusions

- 11-12 g/dL

**Why not transfuse all individuals with
thalassemia intermedia?**

Complications of Low Hemoglobin in Non-Transfused Thalassemia

Children

- **Bone changes: face and head size**
- **Feeding difficulties**
- **Sweating**
- **Lack of weight gain**
- **Growth delay**
- **Splenomegaly**


10-15 years

- **Growth delay**
- **Pubertal delay**
- **Progressive splenomegaly**
- **Facial bone changes**
- **Fatigue**
- **Extramedullary masses**

Adults

- **Extra-medullary masses**
- **Fatigue**
- **Pain**
- **Thrombosis**
- **Pulmonary hypertension,**
- **Cerebral vasculopathy**
- **Leg ulceration**
- **Fractures**

Transfusions have become very safe, but still have risks



Risks

- Iron overload
- Antibody formation
- Viral infections
- More hospital visits

Benefits

- Activity, appetite, growth
- Prevent bone changes
- Prevent spleen enlargement

Role of Splenectomy


- Splenectomy is no longer recommended to delay or prevent transfusions
 - Transfusions are safer
 - More risks of splenectomy in the long term
 - Many patients will still require transfusions later on
- But, progressive splenomegaly worsens anemia
 - So, splenomegaly should be prevented by early recognition and starting transfusions
 - Splenomegaly is reversible in the first decade, but not later on

Deciding on chronic transfusions

- Beta/Beta thalassemia
 - Baseline hemoglobin <7 g/dL, with or without symptoms
 - Or
 - Baseline hemoglobin >7 g/dL AND ***symptoms of anemia***
- E Beta Thalassemia
 - Symptoms of anemia
- Hemoglobin H Disease
 - Intermittent transfusions in Hb H Constant Spring
 - Transfusions are not needed in deletional Hb H disease

Beta Thalassemia Major: Natural History

Transfused & Chelated



Options for Non-Transfused Thalassemia

- Hydroxyurea
 - Effective in a subgroup of patients with beta thalassemia intermedia
- Luspatercept (investigational)
 - Improves survival of red blood cell that are forming in the bone marrow
 - Initial clinical trial in transfusion-dependent thalassemia
 - Future trial in non-transfused thalassemia
- Hepcidin or hepcidin-mimics (investigational)
 - Expected to improve alpha:beta imbalance
 - No current clinical trials in non-transfused thalassemia

Cure for thalassemia

- Bone marrow transplant
 - Siblings
 - Unrelated donors
- Gene therapy
 - Lentiviral vectors
 - Gene Editing